Fisher Asset Management LLC Has $2.83 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA

Fisher Asset Management LLC lowered its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 29.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 102,259 shares of the company’s stock after selling 41,992 shares during the period. Fisher Asset Management LLC owned approximately 0.14% of Kiniksa Pharmaceuticals International worth $2,830,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of KNSA. Quadrature Capital Ltd bought a new position in Kiniksa Pharmaceuticals International in the 2nd quarter valued at about $289,000. AXQ Capital LP acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $289,000. Franklin Resources Inc. increased its stake in Kiniksa Pharmaceuticals International by 62.2% in the second quarter. Franklin Resources Inc. now owns 108,574 shares of the company’s stock valued at $3,004,000 after acquiring an additional 41,632 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new position in Kiniksa Pharmaceuticals International during the second quarter valued at approximately $5,550,000. Finally, Catalyst Funds Management Pty Ltd acquired a new position in Kiniksa Pharmaceuticals International during the second quarter valued at approximately $493,000. Institutional investors own 53.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on KNSA shares. TD Cowen began coverage on shares of Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They set a “buy” rating and a $60.00 target price on the stock. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. The Goldman Sachs Group lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Wedbush reiterated an “outperform” rating and issued a $48.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Tuesday. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $52.00.

Kiniksa Pharmaceuticals International Trading Up 1.7%

Shares of KNSA stock opened at $41.67 on Friday. The stock has a market cap of $3.16 billion, a price-to-earnings ratio of 92.60 and a beta of 0.02. The stock has a 50-day moving average of $39.56 and a 200-day moving average of $33.93. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $42.98.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The company had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.Kiniksa Pharmaceuticals International’s revenue was up 61.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.18) earnings per share. Sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 97,390 shares of the stock in a transaction dated Wednesday, October 22nd. The stock was sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the completion of the sale, the chief executive officer directly owned 111,794 shares in the company, valued at approximately $4,340,961.02. This trade represents a 46.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John F. Paolini sold 82,542 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Friday, October 31st. The stock was sold at an average price of $37.14, for a total value of $3,065,609.88. Following the completion of the transaction, the insider directly owned 61,324 shares of the company’s stock, valued at approximately $2,277,573.36. This trade represents a 57.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 494,439 shares of company stock worth $19,066,573. Corporate insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.